Cargando…

Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer

BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaka, Masahito, Ikeda, Fusao, Tsujie, Masaki, Yoshioka, Shinichi, Nakamoto, Yoshihiko, Ishii, Takaaki, Kyogoku, Takahisa, Kato, Takeshi, Tsuji, Akihito, Kobayashi, Michiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/
https://www.ncbi.nlm.nih.gov/pubmed/27468238
http://dx.doi.org/10.2147/OTT.S104140
_version_ 1782442829179518976
author Kotaka, Masahito
Ikeda, Fusao
Tsujie, Masaki
Yoshioka, Shinichi
Nakamoto, Yoshihiko
Ishii, Takaaki
Kyogoku, Takahisa
Kato, Takeshi
Tsuji, Akihito
Kobayashi, Michiya
author_facet Kotaka, Masahito
Ikeda, Fusao
Tsujie, Masaki
Yoshioka, Shinichi
Nakamoto, Yoshihiko
Ishii, Takaaki
Kyogoku, Takahisa
Kato, Takeshi
Tsuji, Akihito
Kobayashi, Michiya
author_sort Kotaka, Masahito
collection PubMed
description BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity. PATIENTS AND METHODS: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years. RESULTS: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure, PFS, and OS were 5.3, 13.3, and 38.9 months, respectively. CONCLUSION: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients.
format Online
Article
Text
id pubmed-4944910
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49449102016-07-27 Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer Kotaka, Masahito Ikeda, Fusao Tsujie, Masaki Yoshioka, Shinichi Nakamoto, Yoshihiko Ishii, Takaaki Kyogoku, Takahisa Kato, Takeshi Tsuji, Akihito Kobayashi, Michiya Onco Targets Ther Original Research BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity. PATIENTS AND METHODS: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years. RESULTS: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure, PFS, and OS were 5.3, 13.3, and 38.9 months, respectively. CONCLUSION: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients. Dove Medical Press 2016-07-07 /pmc/articles/PMC4944910/ /pubmed/27468238 http://dx.doi.org/10.2147/OTT.S104140 Text en © 2016 Kotaka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kotaka, Masahito
Ikeda, Fusao
Tsujie, Masaki
Yoshioka, Shinichi
Nakamoto, Yoshihiko
Ishii, Takaaki
Kyogoku, Takahisa
Kato, Takeshi
Tsuji, Akihito
Kobayashi, Michiya
Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title_full Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title_fullStr Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title_full_unstemmed Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title_short Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
title_sort observational cohort study focused on treatment continuity of patients administered xelox plus bevacizumab for previously untreated metastatic colorectal cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/
https://www.ncbi.nlm.nih.gov/pubmed/27468238
http://dx.doi.org/10.2147/OTT.S104140
work_keys_str_mv AT kotakamasahito observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT ikedafusao observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT tsujiemasaki observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT yoshiokashinichi observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT nakamotoyoshihiko observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT ishiitakaaki observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT kyogokutakahisa observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT katotakeshi observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT tsujiakihito observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer
AT kobayashimichiya observationalcohortstudyfocusedontreatmentcontinuityofpatientsadministeredxeloxplusbevacizumabforpreviouslyuntreatedmetastaticcolorectalcancer